Accession Number:

ADB164109

Title:

Drug Development Against Viral Diseases.

Descriptive Note:

Annual rept. 1 Feb 90-31 Jan 91,

Corporate Author:

YALE UNIV NEW HAVEN CT SCHOOL OF MEDICINE

Personal Author(s):

• Tignor, Gregory H.

Report Date:

1991-02-01

Pagination or Media Count:

31.0

Abstract:

Quinolamine Riker Laboratories, AVS 1018 was eminently promising in the yellow fever virus primate model. Treatment before and after virus infection protected 5 virus inoculated monkeys from disease for 25 days. Two of 3 untreated cynomolgous monkeys infected with the Asibi strain of yellow fever virus died within 5 days of infection. Viremia in treated-monkeys was delayed and markedly reduced. Measurable alphabeta interferon was present in serum of drug-treated animals weeks after initiating and maintaining drug therapy. Surviving monkeys developed dermal lesions when inoculated with wild-type vaccinia virus. Anti-viral drugs Vaccinia virus Yellow fever virus RA 1.

Descriptors:

• *THERAPY
• *YELLOW FEVER VIRUS
• *VIRUS DISEASES
• DRUGS
• INTERFERON
• LESIONS
• MONKEYS
• PRIMATES
• YELLOW FEVER
• INFECTIOUS DISEASES

Subject Categories:

• Medicine and Medical Research
• Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE